Mesoblast targets AMD and retinopathy
Thursday, 10 July, 2008
Mesoblast [ASX: MSB] today released results from its sister company Angioblast's pre-clinical trials into using adult stem cells to treat ocular diseases association with abnormal blood vessels.
Trials involving 42 non-human primates indicates that an injection of Mesoblast's proprietary adult stem cells combined with an anti-VEGF agent were able to reduce the number of leaking blood vessels - a major cause of ocular disease - more effectively than using an anti-VEGF agent alone.
The combination also reduced the number of subsequent anti-VEGF injections required in the primates.
The results of this trial will comprise part of the company's IND application to the US FDA.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
